Suppr超能文献

与罕见的种系KIT K509I突变相关的肥大细胞增多症表现出分化良好的肥大细胞表型。

Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

作者信息

Chan Eunice Ching, Bai Yun, Kirshenbaum Arnold S, Fischer Elizabeth R, Simakova Olga, Bandara Geethani, Scott Linda M, Wisch Laura B, Cantave Daly, Carter Melody C, Lewis John C, Noel Pierre, Maric Irina, Gilfillan Alasdair M, Metcalfe Dean D, Wilson Todd M

机构信息

Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Research Technologies Section, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Mont.

出版信息

J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.

Abstract

BACKGROUND

Mastocytosis associated with germline KIT activating mutations is exceedingly rare. We report the unique clinicopathologic features of a patient with systemic mastocytosis caused by a de novo germline KIT K509I mutation.

OBJECTIVES

We sought to investigate the effect of the germline KIT K509I mutation on human mast cell development and function.

METHODS

Primary human mast cells derived from CD34(+) peripheral blood progenitors were examined for growth, development, survival, and IgE-mediated activation. In addition, a mast cell transduction system that stably expressed the KIT K509I mutation was established.

RESULTS

KIT K509I biopsied mast cells were round, CD25(-), and well differentiated. KIT K509I progenitors cultured in stem cell factor (SCF) demonstrated a 10-fold expansion compared with progenitors from healthy subjects and developed into mature hypergranular mast cells with enhanced antigen-mediated degranulation. KIT K509I progenitors cultured in the absence of SCF survived but lacked expansion and developed into hypogranular mast cells. A KIT K509I mast cell transduction system revealed SCF-independent survival to be reliant on the preferential splicing of KIT at the adjacent exonic junction.

CONCLUSION

Germline KIT mutations associated with mastocytosis drive a well-differentiated mast cell phenotype distinct to that of somatic KIT D816V disease, the oncogenic potential of which might be influenced by SCF and selective KIT splicing.

摘要

背景

与种系KIT激活突变相关的肥大细胞增多症极为罕见。我们报告了一名由新发种系KIT K509I突变引起的系统性肥大细胞增多症患者独特的临床病理特征。

目的

我们试图研究种系KIT K509I突变对人肥大细胞发育和功能的影响。

方法

对源自CD34(+)外周血祖细胞的原代人肥大细胞进行生长、发育、存活及IgE介导的激活检测。此外,建立了稳定表达KIT K509I突变的肥大细胞转导系统。

结果

KIT K509I活检的肥大细胞呈圆形,CD25(-),且分化良好。与健康受试者的祖细胞相比,在干细胞因子(SCF)中培养的KIT K509I祖细胞扩增了10倍,并发育为成熟的高颗粒肥大细胞,其抗原介导的脱颗粒增强。在无SCF的情况下培养的KIT K509I祖细胞存活,但缺乏扩增,发育为低颗粒肥大细胞。一个KIT K509I肥大细胞转导系统显示,不依赖SCF的存活依赖于KIT在相邻外显子连接处的优先剪接。

结论

与肥大细胞增多症相关的种系KIT突变驱动了一种分化良好的肥大细胞表型,与体细胞KIT D816V疾病不同,其致癌潜力可能受SCF和选择性KIT剪接的影响。

相似文献

1
Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.
2
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Leuk Res. 2014 Oct;38(10):1245-51. doi: 10.1016/j.leukres.2014.07.010. Epub 2014 Aug 1.
3
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
J Allergy Clin Immunol. 2016 Jan;137(1):168-178.e1. doi: 10.1016/j.jaci.2015.05.008. Epub 2015 Jun 19.
5
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Haematologica. 2011 Mar;96(3):459-63. doi: 10.3324/haematol.2010.031690. Epub 2010 Dec 6.
7
The genetic basis of mast cell activation disease - looking through a glass darkly.
Crit Rev Oncol Hematol. 2015 Feb;93(2):75-89. doi: 10.1016/j.critrevonc.2014.09.001. Epub 2014 Sep 28.
8
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Blood. 2004 Apr 15;103(8):3222-5. doi: 10.1182/blood-2003-11-3816. Epub 2003 Dec 24.
9
Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
EBioMedicine. 2019 May;43:150-158. doi: 10.1016/j.ebiom.2019.03.089. Epub 2019 Apr 8.
10
A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
J Immunol Methods. 2013 Apr 30;390(1-2):52-62. doi: 10.1016/j.jim.2013.01.008. Epub 2013 Jan 25.

引用本文的文献

1
Mastocytosis.
Nat Rev Dis Primers. 2025 Apr 24;11(1):30. doi: 10.1038/s41572-025-00611-8.
3
Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.
Int J Mol Sci. 2024 Jan 23;25(3):1401. doi: 10.3390/ijms25031401.
4
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
Cancers (Basel). 2022 Jul 17;14(14):3474. doi: 10.3390/cancers14143474.
5
Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.
Int J Mol Sci. 2021 Mar 4;22(5):2586. doi: 10.3390/ijms22052586.
6
Pediatric Mastocytosis: Recognition and Management.
Am J Clin Dermatol. 2021 Mar;22(2):205-220. doi: 10.1007/s40257-020-00581-5.
7
Recent advances in the understanding and therapeutic management of mastocytosis.
F1000Res. 2019 Nov 22;8. doi: 10.12688/f1000research.19463.1. eCollection 2019.
9
Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis.
Clin Case Rep. 2018 Jul 31;6(9):1834-1840. doi: 10.1002/ccr3.1607. eCollection 2018 Sep.
10
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 mutations and review of the literature.
Oncotarget. 2016 Jul 19;8(40):68950-68963. doi: 10.18632/oncotarget.10711. eCollection 2017 Sep 15.

本文引用的文献

2
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
J Clin Oncol. 2013 Jun 1;31(16):e245-7. doi: 10.1200/JCO.2012.42.0133. Epub 2013 Apr 22.
3
Heterogeneity in the responses of human lung mast cells to stem cell factor.
Clin Exp Allergy. 2013 Jan;43(1):50-9. doi: 10.1111/cea.12045.
4
Alternative transcription and alternative splicing in cancer.
Pharmacol Ther. 2012 Dec;136(3):283-94. doi: 10.1016/j.pharmthera.2012.08.005. Epub 2012 Aug 14.
6
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
J Clin Oncol. 2012 Apr 20;30(12):e126-9. doi: 10.1200/JCO.2011.38.9973. Epub 2012 Feb 27.
7
Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Exp Hematol. 2011 Aug;39(8):859-65.e2. doi: 10.1016/j.exphem.2011.05.009. Epub 2011 May 27.
8
Evaluation of the WHO criteria for the classification of patients with mastocytosis.
Mod Pathol. 2011 Sep;24(9):1157-68. doi: 10.1038/modpathol.2011.84. Epub 2011 May 6.
9
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Haematologica. 2011 Mar;96(3):459-63. doi: 10.3324/haematol.2010.031690. Epub 2010 Dec 6.
10
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.
Genes Dev. 2010 Nov 1;24(21):2343-64. doi: 10.1101/gad.1973010.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验